- Home
- REI vs SPRO Comparison
REI vs SPRO Comparison
Compare REI & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REI
- SPRO
- Stock Information
- Founded
- REI 2004
- SPRO 2013
- Country
- REI United States
- SPRO United States
- Employees
- REI N/A
- SPRO N/A
- Industry
- REI Oil & Gas Production
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- REI Energy
- SPRO Health Care
- Exchange
- REI Nasdaq
- SPRO Nasdaq
- Market Cap
- REI 171.0M
- SPRO 162.1M
- IPO Year
- REI N/A
- SPRO 2017
- Fundamental
- Price
- REI $0.79
- SPRO $2.33
- Analyst Decision
- REI
- SPRO Buy
- Analyst Count
- REI 0
- SPRO 4
- Target Price
- REI N/A
- SPRO $5.00
- AVG Volume (30 Days)
- REI 4.2M
- SPRO 890.8K
- Earning Date
- REI 08-06-2025
- SPRO 08-04-2025
- Dividend Yield
- REI N/A
- SPRO N/A
- EPS Growth
- REI N/A
- SPRO N/A
- EPS
- REI 0.36
- SPRO N/A
- Revenue
- REI $335,642,768.00
- SPRO $44,584,000.00
- Revenue This Year
- REI $2.59
- SPRO N/A
- Revenue Next Year
- REI $17.45
- SPRO N/A
- P/E Ratio
- REI $2.23
- SPRO N/A
- Revenue Growth
- REI N/A
- SPRO N/A
- 52 Week Low
- REI $0.72
- SPRO $0.51
- 52 Week High
- REI $2.00
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- REI 50.53
- SPRO 38.82
- Support Level
- REI $0.75
- SPRO $2.30
- Resistance Level
- REI $0.78
- SPRO $2.45
- Average True Range (ATR)
- REI 0.04
- SPRO 0.14
- MACD
- REI 0.00
- SPRO -0.08
- Stochastic Oscillator
- REI 47.27
- SPRO 3.26
About REI Ring Energy Inc.
Ring Energy Inc is an independent exploration and production company based in The Woodlands, Texas and is engaged in oil and natural gas development, production, acquisition, and exploration activities currently focused in the Permian Basin of Texas. The drilling operations of the company target the oil and liquid rich producing formations in the Northwest Shelf, the Central Basin Platform and the Delaware Basin all of which are part of the Permian Basin in Texas.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.